Memory and Antioxidants in Vascular Impairment Trial

Summary

This is a 24-week randomized, double-blind, placebo-controlled parallel group design study involving Vascular cognitive impairment-no dementia (VCIND) patients to evaluate the efficacy and safety of oral NAC supplementation (2,400 mg daily) as an add-on therapy to improve cognitive function in patients undergoing cardiac rehabilitation (CR). The CR program consists of a harmonized aerobic and resistance training in a supervised group setting. Eligible patients will be randomized to receive NAC (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening) or matching placebo capsules. The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.

Timeline

Start

2018-04-30

Primary completion

2023-09-27

Completion

2023-09-27

Publications

• Gallagher D, Kang Y, Herrmann N, Kiss A, Black SE, Oh P, Marzolini S, Rabin JS, Andreazza A, Ramirez J, Gao F, Rapoport M, Chen JJ, Survilla K, Vieira D, Mah E, Swardfager W, Lanctot KL. Efficacy and safety of N-acetylcysteine in patients with mild cognitive impairment undergoing exercise-based cardiac rehabilitation program: a randomized controlled trial. Alzheimers Res Ther. 2026 Apr 27;18(1):144. doi: 10.1186/s13195-026-02062-z.

Drugs

Indications